No sex‐based differences in odds of starting or time to treatment of generalized myasthenia gravis: A single center cohort study
Open Access
- 26 July 2024
- journal article
- research article
- Published by Wiley in Muscle & Nerve
- Vol. 70 (4) , 774-781
Abstract
Introduction/Aims: Females with generalized myasthenia gravis (gMG) report lower quality of life (QoL) and have more severe disease than males. Sex differences in disease characteristics exist, however whether there are sex differences in the treatment of gMG that may contribute to QoL disparities is unknown. Our objective is to determine whether there are sex differences in the treatment of gMG.Methods: We performed a single‐center retrospective study of people diagnosed with gMG at the University of Calgary between 1997 and 2021. Primary outcome was proportion starting treatment and secondary outcome was time from diagnosis to treatment initiation. Treatments included pyridostigmine, prednisone, steroid sparing therapies (azathioprine, mycophenolate mofetil [MMF], methotrexate [MTX], or tacrolimus), intravenous immunoglobulin (IVIg), plasmapheresis, rituximab, eculizumab, cyclosporine, stem cell transplantation, and thymectomy. Multivariable logistic and Cox proportional hazards regression models were used to examine treatment associations with sex, adjusted for time from onset to diagnosis, age at diagnosis, presence of thymoma, and antibody status.Results: A total of 179 people with gMG were included (41.9% female). Odds of starting treatment were not statistically associated with sex after adjustment for confounders and correction for multiple testing. Results of the secondary analysis using time to treatment initiation as the outcome were similar.Discussion: We found no sex differences in odds of starting treatment or time to treatment initiation that might explain previously observed sex‐based differences in QoL. Future work should capture physician and patient treatment preferences that may influence disease management.Keywords
This publication has 25 references indexed in Scilit:
- Incidence and prevalence of myasthenia gravis in the United States: A claims‐based analysisMuscle & Nerve, 2023
- Gender differences in clinical outcomes in myasthenia gravis: A prospective cohort studyMuscle & Nerve, 2021
- Burden of illness in patients with treatment refractory myasthenia gravisMuscle & Nerve, 2018
- Gender and quality of life in myasthenia gravis patients from the myasthenia gravis foundation of America registryMuscle & Nerve, 2018
- International clinimetric evaluation of the MG‐QOL15, resulting in slight revision and subsequent validation of the MG‐QOL15rMuscle & Nerve, 2016
- A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravisJournal of Autoimmunity, 2014
- Sex disparity in resuscitation efforts and outcomes in out-of-hospital cardiac arrestThe American Journal of Emergency Medicine, 2012
- Stroke in Women: Disparities and OutcomesCurrent Cardiology Reports, 2010
- Lifetime course of myasthenia gravisMuscle & Nerve, 2007
- Prognosis of myasthenia gravis: a retrospective study of 380 patientsJournal of Neurology, 1997